Cycle Pharmaceuticals Ltd. has reiterated its interest in acquiring Vanda Pharmaceuticals Inc., even after a recent setback concerning one of Vanda’s drugs. The Cambridge, UK-based company has maintained its $488 million offer, which translates to an $8-per-share bid. This announcement follows a previous report by Bloomberg News, underscoring Cycle’s determination despite Vanda’s board expressing opposition...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here